NTAGI to soon chalk out roadmap to introduce Zydus Cadila’s vaccine in Covid inoculation drive

By: |
August 25, 2021 4:02 PM

NTAGI Chairman Dr N K Arora said it is estimated that there are around 12 crore adolescents in the age group of 12-18 years in India and less than 1 per cent of them may have comorbidities.

NTAGI Chairman Dr N K Arora, DNA-based needle-free COVID-19 vaccine ZyCoV-D, oadmap for introducing Zydus Cadila's Covid vaccine , priority list with the focus being on adolescents aged 12-18 yearsCovishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose

The National Technical Advisory Group on Immunisation (NTAGI) will soon hold a meeting to devise a roadmap for introducing Zydus Cadila’s Covid vaccine in the inoculation drive and prioritising beneficiaries focusing on those aged 12-18 years with comorbidities.

The indigenously developed world’s first DNA-based needle-free COVID-19 vaccine ZyCoV-D received Emergency Use Authorisation from the drug regulator on August 20 making it the first vaccine to be administered in the age group of 12-18 years in the country.

NTAGI Chairman Dr N K Arora said it is estimated that there are around 12 crore adolescents in the age group of 12-18 years in India and less than 1 per cent of them may have comorbidities.

“The NTAGI’s meeting will be held soon to chalk out a roadmap for introducing the three-dose ZyCoV-D vaccine in the ongoing COVID-19 vaccination drive. The meeting will also focus on prioritisation of beneficiaries as this vaccine is approved for both adolescents and adults,” he said.

“The aim is to develop a priority list with the focus being on adolescents aged 12-18 years with comorbidities,” Dr Arora said.
The NTAGI will provide the protocol and framework for the introduction of this vaccine in the COVID-19 immunisation drive.
Covishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose, these are administered in two doses.

The Department of Biotechnology (DBT) has said that ZyCoV-D is the world’s first DNA-based vaccine against the coronavirus and when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance.

It said that interim results from Phase-III clinical trials in over 28,000 volunteers showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19, the DBT said. The vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive Phase one and two clinical trials. Both Phase one/two and Phase three clinical trials have been monitored by an independent data safety monitoring board, it added

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Centre keen to provide efficient, inclusive healthcare services to people of Jammu and Kashmir: Union Health Minister Mansukh Mandaviya
2UK to roll out life-saving COVID-19 treatment which was given to Donald Trump
3COVID-19: Centre asks states to analyse situation, strengthen health infrastructure